Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 results highlighted by a 196% year-over-year increase in Nociscan scan volumes, reflecting accelerating clinical adoption and integration into physician workflows. The company also achieved a 64% sequential growth from Q4 2025, driven by new account activations and deeper utilization within existing sites. Aclarion believes this momentum positions Nociscan to address a potential $2 billion market opportunity, given that approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain.
Reimbursement progress has been a key catalyst, with Nociscan now reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. This early payer adoption provides a pathway for broader coverage expansion. Additionally, Aclarion launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, available here. The company continues engagement with U.S. payers through its Nociscan Reimbursement Program.
Clinically, Aclarion is advancing the CLARITY randomized trial, with a preliminary internal readout expected in the second half of 2026 and public disclosure of early interim results anticipated in late 2026. Seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials are underway to support reimbursement discussions and potential local coverage decisions by commercial insurers.
The company strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide. Financially, Aclarion reported $19.0 million in cash as of March 31, 2026, with no debt and 2,444,871 common shares outstanding. The company also announced a $2.5 million share repurchase program and believes its cash runway extends into the second half of 2027.
“Q1 represents a clear inflection for Aclarion,” said Brent Ness, Chief Executive Officer. “Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.”
